Salvage chemotherapy according to the ASHAP protocol: A single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas

Annals of Hematology

Volumn 82, Issue 8, 2003, Pages 481-486

  Nückel, Holger ^a   Durig J ^a   Duhrsen U ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

ASHAP; Non Hodgkin's lymphoma; Radiotherapy; Relapse; Salvage chemotherapy; Toxicity

Indexed keywords

CARMUSTINE; CISPLATIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; MELPHALAN; METHYLPREDNISOLONE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; ENZYME ACTIVITY; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; INFECTION; KIDNEY DISEASE; MALE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SALVAGE THERAPY; SCORING SYSTEM; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COHORT STUDIES; CYTARABINE; DOXORUBICIN; FEMALE; HUMANS; LONGITUDINAL STUDIES; LYMPHOMA, NON-HODGKIN; MALE; METHYLPREDNISOLONE HEMISUCCINATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0042355611     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0678-1     Document Type: Article

References (32)

1. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329: 987-994
2. Armitage P, Berry G (1987) Statistical methods in medical research. Blackwell Scientific, Oxford, pp 125-132
3. Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, Hagenbeek A, Somers R, Chauvin F, Philip T (1998) The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 92:3562-3568
4. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886
5. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ (1982) IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60:693-697
6. Cabanillas F, Hagemeister FB, McLaughlin P, Velasquez WS, Riggs S, Fuller L, Smith T (1987) Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 5:407-412
7. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244
8. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den NE, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242
9. Ezzat AA, Khalifa F, Berry J, Khan B, Raja MA, Abdel-Warith A (1994) E-SHAP: an effective treatment in selected patients with relapsed non-Hodgkin's lymphoma. Ann Oncol 5:453-456
10. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Jr, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006
11. Girouard C, Dufresne J, Imrie K, Stewart AK, Brandwein J, Prince HM, Pantolony D, Keating A, Crump M (1997) Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol 8:675-680
12. Hanel M, Kroger N, Hoffknecht MM, Peters SO, Metzner B, Fiedler F, Braumann D, Schubert JC, Illiger HJ, Hanel A, Kruger WH, Zeller W, Weh HJ, Hossfeld DK, Zander AR (2000) ASHAP - an effective salvage therapy for recurrent and refractory malignant lymphomas. Ann Hematol 79:304-311
13. Hiddemann W, Longo DL, Coiffier B, Fisher RI, Cabanillas F, Cavalli F, Nadler LM, De Vita VT, Lister TA, Armitage JO (1996) Lymphoma classification - the gap between biology and clinical management is closing. Blood 88:4085-4089
14. Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A (2000) Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? J Clin Oncol 18:332-339
15. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assess 53:457
16. Kewalramani T, Zelenetz AD, Hedrick EE, Donnelly GB, Hunte S, Priovolos AC, Qin J, Lyons NC, Yahalom J, Nimer SD, Moskowitz CH (2000) High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 96:2399-2404
17. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV (1993) Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 341:1051-1054
18. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26
19. Peto R, Peto J (1972) Asymptotically efficient rank invariation test procedures (with discussion). J R Stat Soc 135:185
20. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone AH, Gorin NC, Flesh M (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316:1493-1498
21. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der LH, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545
22. Press OW, Livingston R, Mortimer J, Collins C, Appelbaum F (1991) Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 9:423-431
23. Reiser M, Josting A, Dias WP, Draube A, Scheid C, Tesch H, Wolf J, Diehl V, Engert A (1999) Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma. Leuk Lymphoma 33:305-312
24. Rodriguez J, Rodriguez MA, Fayad L, McLaughlin P, Swan F, Sarris A, Romaguera J, Andersson B, Cabanillas F, Hagemeister FB (1999) ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 93:3632-3636
25. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117-122
26. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F (1994) ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 12:1169-1176
27. Velasquez W, Dunphy F, Petruska PJ, Adkins D, Broun GO Jr, Spitzer G (1995) ASHAP with or without ABMT for high risk non-Hodgkin's lymphoma (NHL) (abstract 1205). Proc Am Soc Clin Oncol 14:387
28. Velasquez W, Dunphy F, Santillana S, Adkins D, Browers C, Broun GO Jr, Petruska PJ, Spitzer G (1993) ASHAP, an effective treatment for relapsing and refractory Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) (abstract 538). Blood 82 [Suppl 1]:138a
29. Villela L, Lopez-Guillermo A, Montoto S, Rives S, Bosch F, Perales M, Ferrer A, Esteve J, Colomo L, Campo E, Montserrat E (2001) Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer 91:1557-1562
30. Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO, Pavlovsky S, Keating A, Yanes B, van Besien K, Armitage JO, Horowitz MM (2001) Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 19:406-413
31. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD (1993) EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 11:1573-1582
32. Zhang L, Yu D, Hicklin DJ, Hannay JA, Ellis LM, Pollock RE (2002) Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res 62:2034-2042